ArticleCancer medicine2026
Ramelteon and Mortality in Patients With Sepsis and Cancer: Insights From a Propensity-Matched Analysis of the MIMIC-IV Database.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the association between ramelteon use and mortality outcomes in patients with sepsis and cancer. The research question was whether ramelteon use is associated with reduced mortality in this high-risk patient population.
methodsA retrospective analysis of the MIMIC-IV database was conducted. We included 3283 patients with sepsis and cancer, with 424 receiving ramelteon and 2859 not receiving ramelteon. Missing data (< 20%) were imputed using random forest. Propensity score matching (PSM) was used to balance baseline characteristics between groups (1:1 matching, caliper width of 0.1), resulting in 400 patients in each group. Kaplan-Meier curves were used to compare survival probabilities, and Cox regression and logistic regression analyses were performed to assess the association between ramelteon and mortality outcomes.
resultsRamelteon use was significantly associated with lower 30-day (HR: 0.37, 95% CI: 0.28-0.50, p < 0.001), 90-day (HR: 0.39, 95% CI: 0.29-0.52, p < 0.001), ICU (OR: 0.29, 95% CI: 0.18-0.46, p < 0.001), and in-hospital mortality (OR: 0.50, 95% CI: 0.35-0.72, p < 0.001) in the fully adjusted model after PSM. In exploratory duration-related analyses, ramelteon use for ≤ 7 days was associated with lower mortality, whereas no additional significant association was observed with longer duration.
conclusionRamelteon use was associated with lower mortality among patients with sepsis and cancer. However, given the observational design and potential residual confounding, these findings should be interpreted as hypothesis-generating and require confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.